Repositioning Candidate Details
| Candidate ID: | R0625 |
| Source ID: | DB04852 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Implitapide |
| Synonyms: | Implitapide |
| Molecular Formula: | C35H37N3O2 |
| SMILES: | CC1=NC2=C(C3=CC=CC=C3N2CC2=CC(=CC=C2)[C@H](C2CCCC2)C(=O)N[C@@H](CO)C2=CC=CC=C2)C(C)=C1 |
| Structure: |
|
| DrugBank Description: | Implitapide is a microsomal triglyceride transfer protein (MTP)-inhibitor. |
| CAS Number: | 177469-96-4 |
| Molecular Weight: | 531.6872 |
| DrugBank Indication: | For the treatment of atherosclerosis. |
| DrugBank Pharmacology: | Implitapide is an inhibitor of microsomal triglyceride transfer protein (MTP), a key enzyme involved in the assembly and release of cholesterol and triglyceride from the liver and intestinal tract. It is being investigated for the treatment of atherosclerosis. |
| DrugBank MoA: | MTP mediates triglyceride absorption and chylomicron secretion from the intestine and very-low-density lipoprotein (VLDL) secretion from the liver by linking lipid molecules with apolipoprotein B (apoB). Inhibition of MTP reduces the level of all apoB-containing lipoproteins, including LDL. |
| Targets: | Microsomal triglyceride transfer protein large subunit |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I07 | 1936 | Arteriosclerosis | Build-up of fatty material and calcium deposition in the arterial wall resulting in partial or complete occlusion of the arterial lumen.https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C35768 | disease of anatomical entity/cardiovascular system disease/ vascular disease/ artery disease | Details |